Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HSP90AA1 | P07900 | 17/20 | 0.80 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Geldanamycin SCHEMBL16669998 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14626015 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL13928050 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14399626 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL12671560 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL254142 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL17973297 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL14583125 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL13101681 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 | |
| Geldanamycin SCHEMBL13204561 | 1.00 | ALDH1A1 (1.00) | ALDH1A1HSP90AA1ERBB2HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283343-B2 | Ansamycin formulations and methods of use thereof | INFINITY PHARMACEUTICALS INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2492261-A1 | Analogs of benzoquinone-containing ansamycins for the treatment of cancer | Infinity Discovery, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| US-8252779-B2 | Analogs of benzoquinone-containing ansamycins and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20120058982-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8003634-B2 | Analogs of benzoquinone-containing ansamycins and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110086110-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | INFINITY DISCOVERY, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-1904057-B1 | HYDROQUINONE ANSAMYCINS IN THE TREATMENT OF GASTROINTESTINAL STROMAL TUMORS | INFINITY DISCOVERY INC (US) | 2009-12-16 | — | — | EP | disclosed |
| US-7579337-B2 | Analogs of benzoquinone-containing ansamycins and methods of use thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090088414-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | ADAMS JULIAN | 2009-04-02 | — | — | US | disclosed |
| US-20090062528-A1 | Ansamycin formulations and methods of use thereof | AUSTAD BRIAN C | 2009-03-05 | — | — | US | disclosed |
| WO-2008073424-A9 | ANSAMYCIN FORMULATIONS AND METHODS OF USE THEREOF | INFINITY DISCOVERY INC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008073424-A2 | ANSAMYCIN FORMULATIONS AND METHODS OF USE THEREOF | INFINITY DISCOVERY, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088414-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | HSP90B1, CDC37, NPM1 | ALDH1A1 570/4885HSP90AA1 14/4885ERBB2 2318/4885 |
| US-20120058982-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | HSP90B1, CDC37, NPM1 | ALDH1A1 570/4885HSP90AA1 14/4885ERBB2 2318/4885 |
| US-20110086110-A1 | Analogs of Benzoquinone-Containing Ansamycins and Methods of Use Thereof | HSP90B1, CDC37, NPM1 | ALDH1A1 570/4885HSP90AA1 14/4885ERBB2 2318/4885 |
| US-20090062528-A1 | Ansamycin formulations and methods of use thereof | HSP90B1, HSP90AB1, HSP90AA1 | ALDH1A1 2982/4885HSP90AA1 3/4885ERBB2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.